Bellevue Group AG Sells 563,130 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Bellevue Group AG cut its stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 39.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 880,979 shares of the company's stock after selling 563,130 shares during the quarter. Bellevue Group AG owned approximately 2.10% of SI-BONE worth $12,351,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. American Century Companies Inc. grew its stake in SI-BONE by 11.0% in the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after purchasing an additional 236,167 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of SI-BONE by 35.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company's stock valued at $11,791,000 after buying an additional 220,555 shares in the last quarter. Marshall Wace LLP increased its holdings in SI-BONE by 332.5% in the fourth quarter. Marshall Wace LLP now owns 264,523 shares of the company's stock worth $3,709,000 after buying an additional 203,361 shares during the last quarter. First Eagle Investment Management LLC bought a new position in SI-BONE during the fourth quarter valued at approximately $2,600,000. Finally, Tocqueville Asset Management L.P. acquired a new stake in SI-BONE in the fourth quarter valued at approximately $2,383,000. 98.11% of the stock is owned by institutional investors and hedge funds.

SI-BONE Stock Performance

Shares of NASDAQ SIBN traded up $0.21 during trading hours on Friday, hitting $18.54. 473,786 shares of the company's stock were exchanged, compared to its average volume of 368,701. The company's 50-day moving average price is $14.50 and its 200-day moving average price is $14.76. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $19.80. The stock has a market capitalization of $788.49 million, a price-to-earnings ratio of -20.15 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The company had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, sell-side analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on SIBN shares. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research note on Tuesday. Needham & Company LLC reissued a "buy" rating and set a $24.00 target price on shares of SI-BONE in a research report on Tuesday. Finally, Truist Financial upped their price target on SI-BONE from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday.

Insider Activity

In related news, insider Anthony J. Recupero sold 3,311 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the transaction, the insider now directly owns 284,555 shares of the company's stock, valued at $4,026,453.25. This trade represents a 1.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the sale, the senior vice president now directly owns 244,878 shares in the company, valued at $3,462,574.92. This trade represents a 1.26 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,775 shares of company stock valued at $95,711. Insiders own 4.00% of the company's stock.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.